Morgan Stanley Starts Portola Pharmaceuticals (PTLA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
William Blair Starts Portola Pharmaceuticals (PTLA) at Outperform
June 17, 2013 11:52 AM EDTWilliam Blair initiates coverage on Portola Pharmaceuticals (NASDAQ: PTLA) with a Outperform.
Analyst John Sonnier said, "Portola is a unique late-stage drug development company with two wholly owned assets in the cardiovascular space that have demonstrated encouraging clinical data to date. The company's primary focus is in the thromboembolism setting: Its... More
